Table 1. Patient baseline demographic data and clinical characteristics.
| EC-Doc | FEC120 | |
|---|---|---|
| Variable | n=689 | n=675 |
|
Age, years | ||
| Median (range) | 54 (27–71) | 54 (25–71) |
| Mean (s.d.) | 53.3 (9.95) | 53.9 (9.85) |
|
Body mass index, kg m−2 | ||
| Median (range) | 25.9 (15.6–53.5) | 25.9 (16.9–48.2) |
| Mean (s.d.) | 26.8 (5.2) | 26.8 (4.9) |
|
Menopausal status,
n
(%) | ||
| Premenopausal | 252 (36.6) | 253 (37.5) |
| Postmenopausal | 428 (62.1) | 417 (61.8) |
| Unknown | 9 (1.3%) | 5 (0.7) |
|
ECOG performance status,
n
(%) | ||
| 0 | 298 (43.3) | 274 (40.6) |
| 1 | 294 (42.7) | 303 (44.9) |
| 2 | 45 (6.5) | 49 (7.3) |
| 3 | 3 (0.4) | 1 (0.1) |
| 4 | 4 (0.6) | 3 (0.4) |
| Unknown | 45 (6.5) | 45 (6.7) |
|
Histological subtype,
n
(%) | ||
| Ductal | 486 (70.5) | 467 (69.2) |
| Lobular | 144 (20.9) | 142 (21.0) |
| Mixed ductal-lobular | 53 (7.7) | 60 (8.9) |
| Undefined | 6 (0.9) | 6 (0.9) |
|
Tumour location,
n
(%) | ||
| Left | 340 (49.3) | 343 (50.8) |
| Right | 344 (49.9) | 331 (49.0) |
| Unknown | 5 (0.7) | 1 (0.1) |
|
Tumour size,
n
(%) | ||
| T1 | 189 (27.4) | 199 (29.5) |
| T2 | 393 (57.0) | 355 (52.6) |
| T3 | 84 (12.2) | 81 (12.0) |
| T4 | 22 (3.2) | 38 (5.6) |
| Unknown | 1 (0.1) | 2 (0.3) |
|
Number of positive axillary lymph nodes,
n
(%) | ||
| 1–3 (pN1) | 1 (0.1) | 3 (0.4) |
| 4–9 (pN2) | 417 (60.5) | 405 (60.0) |
| ⩾10 (pN3) | 270 (39.2) | 265 (39.3) |
| Unknown | 1 (0.1) | 2 (0.3) |
|
Histological grade,
n
(%) | ||
| Grade 1+2 | 346 (50.2) | 340 (50.4) |
| Grade 3 | 300 (43.5) | 274 (40.6) |
| Unknown | 43 (6.2) | 61 (9.0) |
|
Hormone receptor status,
n
(%) | ||
| Negative | 170 (24.7) | 162 (24.0) |
| Positive | 519 (75.3) | 513 (76.0) |
|
HER2 status,
n
(%) | ||
| Negative | 476 (69.1) | 473 (70.1) |
| Positive | 149 (21.6) | 153 (22.7) |
| Undefined | 64 (9.3) | 49 (7.3) |
|
Additional treatment,
n
(%) | ||
| Radiotherapy after chemotherapy | 591 (85.8) | 570 (84.4) |
| Radiotherapy between chemotherapy courses | 98 (14.2) | 105 (15.6) |
| Endocrine treatment | 84 (12.2) | 73 (10.8) |
Abbreviations: ECOG=European Co-operative Oncology Group; EC-Doc=epirubicin/cyclophosphamide followed by docetaxel; FEC=fluorouracil/epirubicin/cyclophosphamide.